详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition.

文献详情

资源类型：

Pubmed体系：

收录情况： ◇ 自然指数

作者：

机构： [1]Center for Research on Reproduction and Women's Health, University of Pennsylvania, Philadelphia, PA 19104, USA. [2]Department of Obstetrics and Gynecology, West China Medical School, Sichuan University, Chengdu 610041, China. [3]Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, China. [4]Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA. [5]Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA. [6]Wistar Institute, Philadelphia, PA 19104, USA. [7]Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. [8]Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA.

出处：

DOI：

ISSN：

摘要：

Strategies to enhance response to poly(adenosine diphosphate-ribose) polymerase inhibitor (PARPi) in primary and acquired homologous recombination (HR)-proficient tumors would be a major advance in cancer care. We used a drug synergy screen that combined a PARPi, olaparib, with 20 well-characterized epigenetic drugs and identified bromodomain and extraterminal domain inhibitors (BETis; JQ1, I-BET762, and OTX015) as drugs that acted synergistically with olaparib in HR-proficient cancer cells. Functional assays demonstrated that repressed BET activity reduces HR and thus enhances PARPi-induced DNA damage in cancer cells. We also found that inhibition or depletion of BET proteins impairs transcription of BRCA1 and RAD51, two genes essential for HR. Moreover, BETi treatment sensitized tumors to PARP inhibition in preclinical animal models of HR-proficient breast and ovarian cancers. Finally, we showed that the BRD4 gene was focally amplified across 20 types of common cancers. Combination with BETi could greatly expand the utility of PARP inhibition to patients with HR-proficient cancer. Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 1 区

生物

小类 | 1 区细胞生物学 1 区医学：研究与实验

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区细胞生物学 1 区医学：研究与实验

第一作者：

第一作者机构： [1]Center for Research on Reproduction and Women's Health, University of Pennsylvania, Philadelphia, PA 19104, USA. [2]Department of Obstetrics and Gynecology, West China Medical School, Sichuan University, Chengdu 610041, China.

共同第一作者：

通讯作者：

通讯机构： [1]Center for Research on Reproduction and Women's Health, University of Pennsylvania, Philadelphia, PA 19104, USA. [4]Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA. [8]Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA.

推荐引用方式(GB/T 7714)：

APA：

MLA：